Christel Marchand Aprigliano, the CEO of the Diabetes Patient Advocacy Coalition, authored an op-ed that was published today by Crains Cleveland Business. In this op-ed, Ms. Aprigliano discusses the dangers that copay accumulators present for diabetes patients who have historically relied on patient assistance from pharmaceutical manufacturers to afford their insulin. Ms. Aprigliano references the copay accumulator report that was recently published by Aimed Alliance when discussing the legal exposure that employers could face if they implement copay accumulator programs in the health benefits they offer employees. Read the op-ed here.
Last Updated on May 14, 2020 by Aimed Alliance
